Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study
- 15 November 2021
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 49 (3) , 320-329
Abstract
Objective: To describe characteristics and coronavirus disease 2019 (COVID-19) clinical outcomes of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ulcerative colitis (UC) receiving systemic therapies vs the general population.Methods: This descriptive retrospective cohort study used data from the United States Optum deidentified COVID-19 electronic health record dataset (2007–2020). Adults with COVID-19 were stratified into 3 disease cohorts (patients with RA, PsA, or UC who had received systemic therapy) and a comparator cohort not meeting these criteria. Incidence proportions of hospitalization and clinical manifestations of interest were calculated. Using logistic regression analyses, risk of endpoints was estimated, adjusting for demographics and demographics plus comorbidities.Results: This analysis (February 1 to December 9, 2020) included 315,101 patients with COVID-19. Adjusting for demographics, COVID-19 patients with RA (n = 2306) had an increased risk of hospitalization (OR 1.54, 95% CI 1.39–1.70) and in-hospital death (OR 1.61, 95% CI 1.30–2.00) compared with the comparator cohort (n = 311,563). The increased risk was also observed when adjusted for demographics plus comorbidities (hospitalization OR 1.25, 95% CI 1.13–1.39 and in-hospital death OR 1.35, 95% CI 1.09–1.68]). The risk of hospitalization was lower in COVID-19 patients with RA receiving tumor necrosis factor inhibitors (TNFi) vs non-TNFi biologics (OR 0.32, 95% CI 0.20–0.53) and the comparator cohort (OR 0.77, 95% CI 0.51–1.17). The risk of hospitalization due to COVID-19 was similar between patients receiving tofacitinib and the comparator cohort.Conclusion: Compared with the comparator cohort, patients with RA were at a higher risk of more severe or critical COVID-19 and, except for non-TNFi biologics, systemic therapies did not further increase the risk. (ENCePP; registration no. EU PAS 35384)Keywords
This publication has 17 references indexed in Scilit:
- BMI as a Risk Factor for Clinical Outcomes in Patients Hospitalized with COVID‐19 in New YorkObesity, 2020
- COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical OutcomesArthritis & Rheumatology, 2020
- Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International RegistryGastroenterology, 2020
- The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysisInflammatory Bowel Diseases, 2020
- Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryAnnals of the Rheumatic Diseases, 2020
- Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States: A Multicenter Research Network StudyGastroenterology, 2020
- Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysisExpert Opinion on Drug Safety, 2016
- Optum Labs: Building A Novel Node In The Learning Health Care SystemHealth Affairs, 2014
- Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel diseaseJournal of Crohn's and Colitis, 2014
- The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatmentRheumatology, 2012